Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 197

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 197
---
un Kim as a director, effective immediately. Mr. Kim was appointed
as a member of the Company Board’s Audit Committee, filling the vacancy created by the resignation of Inchul Chung, as previously
reported by the Company on Form 8-K filed with the SEC on June 13, 2024 (the “June 13 Form 8-K”). Additionally,
Mr. Kim was appointed as a member of the Compensation Committee of the Company Board (“the Compensation Committee”) and
a member of the M&A Committee, filling vacancies created by the resignation of Mr. Radclyffe Roberts as previously reported on
the June 13 Form 8-K. The Company believes Mr. Kim is well qualified to serve as a director because of his extensive experience
in both legal and investment sectors across various asset classes, demonstrating significant expertise in capital markets. The Company
Board has affirmatively determined that Mr. Kim meets the applicable standards for an independent director under the rules of the
Nasdaq Stock Market LLC. Mr. Kim will not be compensated by the Company for his services as a director. In connection with his appointment,
Mr. Kim has entered into a Letter Agreement and an Indemnity Agreement with the Company on the same terms as the Letter Agreement
and Indemnity Agreement entered into by the directors and officers of the Company at the time of the Company’s initial public offering
and in the form previously filed as Exhibits 10.1 and 10.6, respectively, to the Company’s Annual Report on Form 10-K filed
with the SEC on April 17, 2024. Other than the foregoing, Mr. Kim is not a party to any arrangement or understanding with any
person pursuant to which he was appointed as director, nor is he party to any transactions required to be disclosed under Item 404(a)
of Regulation S-K involving the Company.

As previously disclosed on the Company’s Current Report filed
on Form 8-K on March 25, 2025, on March 24, 2025 the Company Board appointed Dr. Constance Höfer as the Company’s Chief
Scientific Officer, effective on that date. Dr. Höfer is a seasoned leader in drug development with over 20 years of experience in
oncology and immunology and will oversee the Company’s scientific strategy and innovation pipeline.. Coupled with her extensive
industry experience and a